¶ Trazodone for Sleep and Cognition in Early Alzheimer's Disease
NCT05282550 is a Phase 2 clinical trial conducted at Johns Hopkins University evaluating the use of trazodone for improving sleep quality and cognitive function in patients with early Alzheimer's disease (AD). This trial addresses a critical unmet need: sleep disturbances are extremely common in AD, affecting 40-50% of patients, and are both a consequence and contributor to disease progression.
The trial is particularly significant because it investigates an existing, well-established medication for a novel indication in neurodegeneration. Trazodone is already widely prescribed for insomnia in the general population, and this trial seeks to determine whether it can provide similar benefits in the AD population while potentially modulating disease-relevant pathological processes.
Sleep disturbances in AD represent a bidirectional relationship with disease pathology, where each exacerbates the other in a vicious cycle:
Prevalence and Impact
- 40-50% of AD patients experience significant sleep disturbances
- Sleep problems often appear before cognitive symptoms
- Disturbances worsen as disease progresses
- Associated with increased behavioral symptoms
- Significantly impacts caregiver well-being
Types of Sleep Disturbances
| Type |
Description |
Prevalence in AD |
| Insomnia |
Difficulty initiating/maintaining sleep |
40-60% |
| Sleep fragmentation |
Frequent nighttime awakenings |
50-70% |
| Circadian rhythm changes |
Advanced sleep phase, irregular patterns |
30-50% |
| Excessive daytime sleepiness |
Daytime naps, reduced alertness |
25-40% |
| REM sleep behavior |
Loss of muscle atonia during REM |
20-30% |
¶ Bidirectional Relationship: Sleep and AD Pathology
The relationship between sleep and AD is bidirectional, creating a self-perpetuating cycle:
Sleep Disruption Accelerates AD Pathology
- Glymphatic system clearance is sleep-dependent
- Amyloid-β accumulation increases with sleep disruption
- Tau pathology spreads during sleep
- Sleep deprivation impairs synaptic homeostasis
- Inflammation increases with poor sleep
AD Pathology Disrupts Sleep
- Amyloid deposition in sleep-wake centers
- Tau pathology in hypothalamic nuclei
- Neurotransmitter system dysfunction
- Circadian rhythm generator damage
- Sleep architecture abnormalities
This bidirectional relationship means that treating sleep disturbances may have disease-modifying effects beyond symptomatic improvement.
¶ Current Treatment Landscape
Current options for sleep disturbances in AD are limited:
Pharmacological Approaches
- Benzodiazepines: Effective but significant risks in elderly
- Z-drugs (zolpidem, eszopiclone): Risks include falls, confusion
- Antipsychotics: Reserved for severe agitation, significant risks
- Antihistamines: Cognitive side effects, anticholinergic risk
- Melatonin: Limited efficacy data in AD
Non-Pharmacological Approaches
- Sleep hygiene education
- Light therapy
- Cognitive behavioral therapy for insomnia (CBT-I)
- Regular exercise
- Environmental modifications
Why Trazodone?
- Well-established safety profile
- Non-benzodiazepine mechanism
- Low anticholinergic burden
- Dual sleep promotion and potential neuroprotective effects
- Extensive clinical experience in older adults
¶ Trazodone: Pharmacology and Mechanisms
Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) with complex pharmacology:
Classification
- Chemical class: Triazolopyridine derivative
- Primary mechanism: 5-HT2A antagonist, 5-HT1A partial agonist
- Secondary effects: α1-adrenergic blockade, histamine H1 blockade
- Metabolite: mCPP (meta-chlorophenylpiperazine)
Pharmacokinetics
- Oral bioavailability: High (>90%)
- Peak plasma time: 1-2 hours
- Half-life: 5-9 hours (extended in elderly)
- Metabolism: hepatic (CYP3A4)
- Excretion: renal
Trazodone promotes sleep through multiple mechanisms:
1. 5-HT2A Receptor Antagonism
- Blocks serotonergic excitation
- Promotes sleep continuity
- Reduces sleep fragmentation
- Minimal next-day sedation
2. 5-HT1A Partial Agonism
- Modulates sleep architecture
- May enhance deep sleep
- anxiolytic effects support sleep
3. α1-Adrenergic Blockade
- Reduces arousal
- Promotes sedation
- May contribute to hypotension risk
4. Histamine H1 Blockade
- Sedative effects
- Counteracts daytime alertness
5. mCPP Metabolite
- Complex effects on sleep
- May contribute to sleep architecture
Beyond sleep promotion, trazodone may have disease-relevant effects:
Serotonergic Neuroprotection
- 5-HT2A modulation may affect amyloid processing
- Serotonergic system preservation in AD
- Anti-inflammatory effects via serotonin pathways
mCPP-Mediated Effects
- 5-HT2C modulation may influence cognition
- Potential effects on neurogenesis
- Unknown significance in AD
Indirect Benefits
- Improved sleep → enhanced glymphatic clearance
- Reduced behavioral symptoms
- Better caregiver sleep and well-being
- Potential slowdowns in disease progression
¶ Trial Design and Methods
The NCT05282550 trial employs a rigorous design:
| Parameter |
Value |
| Phase |
Phase 2 |
| Design |
Randomized, double-blind, placebo-controlled |
| Duration |
24 weeks |
| Sample Size |
~100 participants |
| Sponsor |
Johns Hopkins University |
| Lead Investigator |
Dr. Adam P. Spira |
Inclusion Criteria
- Age 60-85 years
- Diagnosis of early AD (MCI due to AD or mild AD dementia)
- Clinically significant sleep disturbance (ISI score >7)
- Stable cholinesterase inhibitor or memantine use (if applicable)
- Reliable caregiver available
- Able to undergo polysomnography
Exclusion Criteria
- Severe depression (MADRS > 20)
- Uncontrolled sleep disorders (obstructive sleep apnea, restless legs syndrome)
- Use of other sedating medications
- Significant cardiovascular disease
- Prior trazodone use for sleep
- Severe medical conditions
| Arm |
Treatment |
Dose |
Schedule |
| Active |
Trazodone |
25-150 mg (flexible) |
Nightly, as needed |
| Placebo |
Matching placebo |
Same regimen |
Nightly, as needed |
Dosing Strategy
- Low starting dose: 25 mg
- Flexible titration up to 150 mg based on response
- As-needed use (not nightly required)
- Allows for individual optimization
- Minimizes unnecessary exposure
Primary Endpoints
-
Sleep efficiency (polysomnography)
- Primary objective measure
- Percentage of time in bed spent sleeping
- Direct measure of sleep quality
-
Cognitive function (ADAS-Cog13)
- Primary clinical endpoint
- Comprehensive cognitive assessment
- Sensitive to early AD changes
Secondary Endpoints
- Sleep quality (PSQI - Pittsburgh Sleep Quality Index)
- Neuropsychiatric symptoms (NPI)
- Actigraphy measures (home sleep monitoring)
- Caregiver burden
- CSF biomarkers (optional sub-study)
- Brain imaging (optional sub-study)
Exploratory Endpoints
- Nighttime sleep architecture (REM, NREM stages)
- Daytime alertness
- Inflammatory markers
| Visit |
Timing |
Assessments |
| Screening |
-4 weeks |
Medical history, physical, cognitive testing |
| Baseline |
Day 0 |
PSG setup, cognitive testing, labs |
| Visit 2 |
Week 4 |
Safety, sleep diary, titration review |
| Visit 3 |
Week 12 |
Primary efficacy assessments |
| Visit 4 |
Week 24 |
Final assessments, PSG |
Sample Size Calculation
- Power: 80%
- Alpha: 0.05 (two-sided)
- Expected effect size: 0.5 (medium)
- Anticipated dropout: 15%
Analysis Methods
- Mixed-effects model for repeated measures
- Intention-to-treat population
- Per-protocol sensitivity analysis
¶ Rationale and Hypothesis
The trial is based on several key premises:
1. Sleep Disturbances Are Modifiable
- Unlike amyloid and tau pathology, sleep can be directly improved
- Existing effective treatments for sleep in general population
- Even partial improvement may have meaningful impact
2. Early Intervention May Be Most Effective
- Early AD may have more reserve to benefit
- Sleep improvements may slow downstream pathology
- Earlier treatment may prevent cascade of complications
3. Bidirectional Relationship Can Be Broken
- Improving sleep may reduce pathology accumulation
- Reducing pathology may improve sleep
- Potential synergistic benefits over time
The trial tests the primary hypothesis that:
Trazodone will improve sleep efficiency and slow cognitive decline in patients with early AD compared to placebo.
Secondary Hypotheses
- Sleep improvement will correlate with reduced AD biomarker changes
- Benefits will be maintained throughout the 24-week treatment period
- Caregiver burden will be reduced with improved patient sleep
If successful, this trial would:
- Validate a new approach to AD symptom management
- Provide disease-modifying potential through sleep improvement
- Establish safety of trazodone in early AD population
- Inform precision medicine for sleep-focused interventions
- Reduce caregiver burden through improved patient sleep
Previous research suggests the following outcomes are plausible:
Sleep Outcomes
- Sleep efficiency improvement: 5-10% over baseline
- Reduced nighttime awakenings: 20-30% reduction
- Improved sleep continuity
- Enhanced daytime alertness
Cognitive Outcomes
- Stabilization of cognitive decline (slower progression)
- Potential small improvements in attention and executive function
- Possible benefits in memory consolidation
Secondary Outcomes
- Reduced behavioral symptoms
- Improved quality of life
- Decreased caregiver burden
Trazodone offers an attractive risk-benefit profile:
Potential Benefits
- Established efficacy for insomnia
- Well-characterized safety in elderly
- Low anticholinergic burden (important in AD)
- Affordable and accessible
Potential Risks
- Orthostatic hypotension (monitor in elderly)
- Next-day sedation (dose-dependent)
- Rare priapism (relevant for patient counseling)
- Serotonin syndrome (rare with monotherapy)
- Cardiac conduction effects (uncommon)
Risk Mitigation
- Low starting dose
- Flexible titration
- Careful monitoring
- Patient/caregiver education
Several smaller studies have investigated trazodone in AD:
| Study |
N |
Duration |
Key Findings |
| Le Bon (2007) |
14 |
4 weeks |
Improved sleep, no cognitive worsening |
| Shaw (2012) |
25 |
8 weeks |
Improved sleep efficiency |
| Shapira (2024) |
45 |
12 weeks |
Improved sleep architecture |
| NCT05282550 |
~100 |
24 weeks |
Largest, longest trial |
The NCT05282550 trial extends prior work:
- Largest sample: Provides adequate power for efficacy detection
- Longest duration: 24 weeks allows assessment of sustained effects
- Polysomnography: Objective sleep measurement
- Cognitive endpoints: Direct assessment of cognitive impact
- Biomarker sub-study: Optional mechanistic insights
- Early AD focus: Most relevant for disease modification
A positive result would:
- Establish trazodone as standard of care for sleep in early AD
- Suggest disease-modifying potential through sleep improvement
- Support investigation of other sleep-targeted therapies
- Inform combination approaches (sleep therapy + disease-modifying drugs)
A negative result would:
- Require examination of methodology (dose, duration, population)
- Prompt investigation of alternative sleep treatments
- Suggest that sleep improvement alone may be insufficient
- Not diminish importance of sleep management for quality of life
Trazodone has been extensively studied in elderly populations:
Common Side Effects (10-30%)
- Drowsiness (usually diminishes with time)
- Headache
- Dizziness
- Dry mouth
Less Common Side Effects (1-10%)
- Orthostatic hypotension
- Gastrointestinal upset
- Blurred vision
- Urinary retention
Rare but Serious
- Serotonin syndrome (with other serotonergic drugs)
- Cardiac arrhythmias (preexisting heart disease)
- Priapism (0.1%)
Special considerations for AD patients:
- Cognitive effects: Minimal anticholinergic burden
- Falls risk: Lower than benzodiazepines
- Respiratory: Minimal suppression vs. benzodiazepines
- Drug interactions: CYP-mediated, requires review
- Renal/hepatic: Dose adjustment may be needed
If successful, trazodone could be combined with:
-
Disease-modifying therapies
- Anti-amyloid antibodies (lecanemab, donanemab)
- Tau-directed therapies
- Neuroprotective agents
-
Other symptomatic treatments
-
Non-pharmacological interventions
- CBT-I
- Light therapy
- Exercise programs
Future research could identify:
- Sleep phenotype subtypes responsive to treatment
- Genetic predictors of response
- Biomarkers for patient selection
- Optimal treatment duration
The NCT05282550 trial represents a pragmatic, evidence-based approach to addressing sleep disturbances in early Alzheimer's disease. By repurposing an existing medication with a favorable safety profile, this trial could establish a new standard of care that simultaneously improves quality of life and potentially modifies disease progression.
Key Points
- Sleep disturbances affect 40-50% of AD patients
- Bidirectional relationship between sleep and AD pathology
- Trazodone offers a favorable safety profile for elderly patients
- Phase 2 trial uses rigorous methodology (PSG, cognitive endpoints)
- Positive results would establish new treatment paradigm
The trial addresses a critical unmet need while exploring a novel disease-modifying mechanism through sleep improvement, representing a promising approach to AD treatment.